Enriching Chemical Space of Bioactive Scaffolds by New Ring Systems: Benzazocines and Their Metal Complexes as Potential Anticancer Drugs
暂无分享,去创建一个
[1] G. Gasser,et al. Red-Absorbing Ru(II) Polypyridyl Complexes with Biotin Targeting Spontaneously Assemble into Nanoparticles in Biological Media. , 2022, Inorganic chemistry.
[2] V. Brabec,et al. Ruthenium(II)–Tris-pyrazolylmethane Complexes Inhibit Cancer Cell Growth by Disrupting Mitochondrial Calcium Homeostasis , 2022, Journal of medicinal chemistry.
[3] Richard D. Taylor,et al. Rings in Clinical Trials and Drugs: Present and Future , 2022, Journal of medicinal chemistry.
[4] W. Ang,et al. Elucidation of Structure–Activity Relationships in Indolobenzazepine-Derived Ligands and Their Copper(II) Complexes: the Role of Key Structural Components and Insight into the Mechanism of Action , 2022, Inorganic chemistry.
[5] G. Spengler,et al. Highly Antiproliferative Latonduine and Indolo[2,3-c]quinoline Derivatives: Complex Formation with Copper(II) Markedly Changes the Kinase Inhibitory Profile , 2022, Journal of medicinal chemistry.
[6] J. Sessler,et al. Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future. , 2022, Chemical Society reviews.
[7] L. Massai,et al. Proteomics as a tool to disclose the cellular and molecular mechanisms of selected anticancer gold compounds , 2021, Coordination Chemistry Reviews.
[8] I. Baranowska-Bosiacka,et al. Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action , 2021, International journal of molecular sciences.
[9] Ting Guo,et al. Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents , 2020, ChemMedChem.
[10] P. Perego,et al. The rediscovery of platinum-based cancer therapy , 2020, Nature reviews. Cancer.
[11] A. Tesei,et al. Modeling neoplastic disease with spheroids and organoids , 2020, Journal of Hematology & Oncology.
[12] B. El Hassouni,et al. A Brief Guide to Performing Pharmacological Studies In Vitro: Reflections from the EORTC-PAMM Course “Preclinical and Early-phase Clinical Pharmacology” , 2019, AntiCancer Research.
[13] S. Mobin,et al. Mitochondrial Localization of Highly Fluorescent and Photostable BODIPY-Based Ruthenium(II), Rhodium(III), and Iridium(III) Metal Complexes. , 2019, Inorganic chemistry.
[14] D. Colin,et al. Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma , 2019, Scientific Reports.
[15] E. Alessio,et al. NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry , 2019, Molecules.
[16] S. Radulović,et al. Antitumor activity of organoruthenium complexes with chelate aromatic ligands, derived from 1,10-phenantroline: Synthesis and biological activity. , 2019, Journal of inorganic biochemistry.
[17] Seon Woong Lee,et al. BODIPY-based Ru(II) and Ir(III) organometallic complexes of avobenzone, a sunscreen material: Potent anticancer agents. , 2018, Journal of inorganic biochemistry.
[18] H. Rupasinghe,et al. Kinase-targeted cancer therapies: progress, challenges and future directions , 2018, Molecular Cancer.
[19] A. Buschini,et al. Effects of polar substituents on the biological activity of thiosemicarbazone metal complexes. , 2018, Journal of inorganic biochemistry.
[20] Azah Kamilah Muda,et al. Similarity Measure for Molecular Structure: A Brief Review , 2017 .
[21] Richard D. Taylor,et al. Combining Molecular Scaffolds from FDA Approved Drugs: Application to Drug Discovery. , 2017, Journal of medicinal chemistry.
[22] Sasanka Deka,et al. Novel mitochondria targeted copper(ii) complexes of ferrocenyl terpyridine and anticancer active 8-hydroxyquinolines showing remarkable cytotoxicity, DNA and protein binding affinity. , 2017, Dalton transactions.
[23] Christine Unger,et al. Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT–mTOR–S6K signaling and drug responses , 2017, Journal of Cell Science.
[24] Arindam Mukherjee,et al. Anticancer activity of a chelating nitrogen mustard bearing tetrachloridoplatinum(iv) complex: better stability yet equipotent to the Pt(ii) analogue. , 2016, Dalton transactions.
[25] G. Devi,et al. Three-dimensional culture systems in cancer research: Focus on tumor spheroid model. , 2016, Pharmacology & therapeutics.
[26] L. Kenner,et al. Comparison of cancer cells cultured in 2 D vs 3 D reveals differences in AKT / mTOR / S 6-kinase signaling and drug response , 2016 .
[27] C. Unger,et al. Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs , 2015, Investigational New Drugs.
[28] Agnieszka K. Witkiewicz,et al. The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.
[29] S. Radulović,et al. Synthesis, characterization and cytotoxic activity of novel platinum(II) iodido complexes. , 2014, European journal of medicinal chemistry.
[30] P. Sadler,et al. Organoiridium Complexes: Anticancer Agents and Catalysts , 2014, Accounts of chemical research.
[31] Richard D. Taylor,et al. Rings in drugs. , 2014, Journal of medicinal chemistry.
[32] V. Arion,et al. Metal‐Based Indolobenzazepines and Indoloquinolines: From Moderate CDK Inhibitors to Potential Antitumor Drugs , 2013 .
[33] W. Berger,et al. Metal–Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation , 2013, Organometallics.
[34] Daniel V LaBarbera,et al. The multicellular tumor spheroid model for high-throughput cancer drug discovery , 2012, Expert opinion on drug discovery.
[35] P. Dyson,et al. Metal-based antitumour drugs in the post-genomic era: what comes next? , 2011, Dalton transactions.
[36] Xiaoyuan Chen,et al. Apoptosis Imaging: Beyond Annexin V , 2010, The Journal of Nuclear Medicine.
[37] Simone Göschl,et al. Structure-activity relationships of highly cytotoxic copper(II) complexes with modified indolo[3,2-c]quinoline ligands. , 2010, Inorganic chemistry.
[38] D. Dalvie,et al. Chapter 6:Influence of Aromatic Rings on ADME Properties of Drugs , 2010 .
[39] W. Berger,et al. Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy , 2010, JBIC Journal of Biological Inorganic Chemistry.
[40] Tingjun Hou,et al. Drug and Drug Candidate Building Block Analysis , 2010, J. Chem. Inf. Model..
[41] M. Jakupec,et al. Highly cytotoxic copper(II) complexes with modified paullone ligands. , 2010, Inorganic chemistry.
[42] C. Humblet,et al. Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.
[43] F. de Vos,et al. Synthesis, in vitro and in vivo evaluation, and radiolabeling of aryl anandamide analogues as candidate radioligands for in vivo imaging of fatty acid amide hydrolase in the brain. , 2009, Journal of medicinal chemistry.
[44] Martin Krug,et al. Recent advances in the development of multi-kinase inhibitors. , 2008, Mini reviews in medicinal chemistry.
[45] G. Sheldrick. A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.
[46] P. Cohen,et al. The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.
[47] W. Berger,et al. Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy. , 2007, Journal of medicinal chemistry.
[48] L. Kèlland,et al. The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.
[49] Carlo Riccardi,et al. Analysis of apoptosis by propidium iodide staining and flow cytometry , 2006, Nature Protocols.
[50] Peter Ertl,et al. Quest for the rings. In silico exploration of ring universe to identify novel bioactive heteroaromatic scaffolds. , 2006, Journal of medicinal chemistry.
[51] Dong Wang,et al. Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.
[52] Gavin Harper,et al. Drug rings database with web interface. A tool for identifying alternative chemical rings in lead discovery programs. , 2003, Journal of medicinal chemistry.
[53] P. Cohen,et al. The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.
[54] G. Schneider,et al. Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. , 2001, Journal of combinatorial chemistry.
[55] G L Snyder,et al. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. , 2000, European journal of biochemistry.
[56] P. Cohen,et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.
[57] L. Meijer,et al. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. , 1999, Journal of medicinal chemistry.
[58] C. Reutelingsperger,et al. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. , 1998, Cytometry.
[59] G. Bemis,et al. The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.
[60] M. N. Burnett,et al. ORTEP-III: Oak Ridge Thermal Ellipsoid Plot Program for crystal structure illustrations , 1996 .
[61] R. Supino. MTT assays. , 1995, Methods in molecular biology.
[62] H. Fujita. [Anticancer drugs]. , 1995, Nihon rinsho. Japanese journal of clinical medicine.
[63] A. W. Addison,et al. Synthesis, structure, and spectroscopic properties of copper(II) compounds containing nitrogen–sulphur donor ligands; the crystal and molecular structure of aqua[1,7-bis(N-methylbenzimidazol-2′-yl)-2,6-dithiaheptane]copper(II) perchlorate , 1984 .
[64] C. Jørgensen. "Symbiotic" Ligands, Hard and Soft Central Atoms , 1964 .